company background image
IVVD logo

Invivyd NasdaqGM:IVVD Stock Report

Last Price

US$4.00

Market Cap

US$475.4m

7D

25.8%

1Y

210.1%

Updated

27 Mar, 2024

Data

Company Financials +

IVVD Stock Overview

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

IVVD fundamental analysis
Snowflake Score
Valuation4/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Invivyd, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Invivyd
Historical stock prices
Current Share PriceUS$4.00
52 Week HighUS$5.20
52 Week LowUS$0.98
Beta0.61
1 Month Change-7.83%
3 Month Change2.04%
1 Year Change210.08%
3 Year Changen/a
5 Year Changen/a
Change since IPO-80.84%

Recent News & Updates

Recent updates

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Oct 24
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Jul 04
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Mar 19
Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Nov 19
Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Invivyd appoints interim CFO, makes headcount changes

Oct 13

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Sep 12

Adagio Therapeutics GAAP EPS of -$0.47

Aug 15

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Jul 30
We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Adagio names David Hering as permanent CEO and Director

Jul 05

Adagio's Round Trip

Mar 02

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Feb 19
We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Feb 16

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Nov 29

Shareholder Returns

IVVDUS BiotechsUS Market
7D25.8%0.9%0.4%
1Y210.1%10.3%28.8%

Return vs Industry: IVVD exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: IVVD exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is IVVD's price volatile compared to industry and market?
IVVD volatility
IVVD Average Weekly Movement17.5%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: IVVD's share price has been volatile over the past 3 months.

Volatility Over Time: IVVD's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
202085David Heringhttps://invivyd.com

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza.

Invivyd, Inc. Fundamentals Summary

How do Invivyd's earnings and revenue compare to its market cap?
IVVD fundamental statistics
Market capUS$475.39m
Earnings (TTM)-US$169.56m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVVD income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$169.56m
Earnings-US$169.56m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.43
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IVVD perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.